Quest Diagnostics Incorporated

Quest Diagnostics is a leading provider of diagnostic testing and services in the United States. The company offers a wide range of diagnostic information services, including routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing. Its services are delivered under the Quest Diagnostics brand and other brands such as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum. The company serves physicians, hospitals, patients, health plans, government agencies, employers, retailers, pharmaceutical companies, and insurers. Its test portfolio covers areas like cardiometabolic and endocrine disorders, cancer, clinical drug monitoring, infectious diseases, neurology (including Alzheimer's disease), women's health (including prenatal genetic testing), and workplace drug testing. Quest also provides risk assessment services for the life insurance industry and employer population health services such as biometric screenings and flu shots.

Quest Diagnostics is listed on the New York Stock Exchange (NYSE) under the ticker symbol DGX. The company is headquartered in the United States and its shares are traded in US Dollars (USD). As a US-based company listed on a major American exchange, its financial reporting and stock price are denominated in USD, making it accessible to investors through standard US brokerage accounts.

Quest Diagnostics operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry focuses on providing diagnostic testing services, laboratory analysis, and related research to support medical decision-making. As a diagnostics company, Quest plays a critical role in healthcare by offering tests that help detect, monitor, and manage various diseases and health conditions. Its services range from routine blood work to advanced genetic and molecular testing, supporting clinical laboratories, hospitals, and other healthcare providers.

Quest Diagnostics primarily serves the United States market. The company operates a network of laboratories, patient service centers, and phlebotomists in physician offices across the country. It also utilizes call centers and mobile phlebotomists, nurses, and health and wellness professionals to reach patients and consumers. While its operations are concentrated in the US, it provides services to a broad range of customers including physicians, hospitals, health plans, government agencies, employers, retailers, pharmaceutical companies, and insurers. Additionally, it offers risk assessment services for the life insurance industry, which may have an international scope, but its core diagnostic services are US-focused.

Quest Diagnostics generates revenue primarily by providing diagnostic testing and related services. Its business model involves collecting specimens (blood, urine, hair, oral fluid) at patient service centers or through mobile phlebotomists, then analyzing them in its laboratories and reporting results to healthcare providers and patients. The company charges fees for these tests, which are paid by patients, insurers, or other third parties. Additionally, Quest offers healthcare IT solutions for providers and payers, testing and medical director services at hospital laboratories, and extended care services. It also develops in vitro diagnostic tests and provides employer population health services such as biometric screenings and flu shots. Other revenue streams include risk assessment services for life insurers and workplace drug testing programs.